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Abstract
Macrophages are key immune cells found in atherosclerotic plaques
and critically shape atherosclerotic disease development. Targeting
the functional repertoire of macrophages may hold novel
approaches for future atherosclerosis management. Here, we
describe a previously unrecognized role of the epigenomic enzyme
Histone deacetylase 3 (Hdac3) in regulating the atherosclerotic
phenotype of macrophages. Using conditional knockout mice, we
found that myeloid Hdac3 deficiency promotes collagen deposition
in atherosclerotic lesions and thus induces a stable plaque pheno-
type. Also, macrophages presented a switch to anti-inflammatory
wound healing characteristics and showed improved lipid handling.
The pro-fibrotic phenotype was directly linked to epigenetic regula-
tion of the Tgfb1 locus upon Hdac3 deletion, driving smooth muscle
cells to increased collagen production. Moreover, in humans, HDAC3
was the sole Hdac upregulated in ruptured atherosclerotic lesions,
Hdac3 associated with inflammatory macrophages, and HDAC3
expression inversely correlated with pro-fibrotic TGFB1 expression.
Collectively, we show that targeting the macrophage epigenome
can improve atherosclerosis outcome and we identify Hdac3 as a
potential novel therapeutic target in cardiovascular disease.
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Introduction
Atherosclerosis is a lipid-driven chronic inflammatory disease and
the main cause of cardiovascular morbidity and mortality. Macro-
phages are the most prevalent immune cells in atherosclerotic
plaques and play a central role in disease progression (Moore et al,
2013). The abundance of macrophages in atherosclerotic plaques,
often as lipid-laden foam cells, associates with key features of
plaque instability and detrimental clinical outcome (Silvestre-Roig
et al, 2014). Since current medication and intervention strategies
reduce the risk for cardiovascular events only moderately, better
understanding of the regulation of inflammatory mechanisms driv-
ing disease is essential for further development of new therapeutic
approaches.
It is increasingly clear that epigenetic mechanisms govern many
aspects of inflammatory and immune responses. Epigenetic
enzymes regulate histone tail modifications, such as acetylation and
methylation that alter chromatin accessibility and thereby control
transcriptional responses (Arrowsmith et al, 2012). Epigenetic
remodeling of histones regulates macrophages and interventions in
histone modifying enzymes in macrophages strongly affect their
inflammatory repertoire (reviewed in: Hoeksema et al, 2012;
Ivashkiv, 2013; Tabas & Glass, 2013). Particularly, Histone deacety-
lases (Hdacs) regulating the acetylation status of histones are essential
in innate immune responses. Broad spectrum Hdac inhibitors are
well-known anti-inflammatory agents and reduce inflammation and
disease severity in animal models for arthritis, inflammatory bowel
disease, and septic shock (Shakespear et al, 2011). However,
to overcome often-observed unwanted side effects by pan-Hdac
inhibition, current efforts in drug development focus on selectively
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targeting of individual Hdacs to improve applicability in treatment
of disease (Arrowsmith et al, 2012).
We are investigating whether targeting of individual Hdacs is an
approach to skew macrophages to a phenotype that dampens
atherosclerosis development. Recent data show that Hdac3 is essen-
tial for induction of a pro-inflammatory gene program in response to
lipopolysaccharide (Chen et al, 2012) and that Hdac3 deletion
renders macrophages more susceptible to alternative activation
(Mullican et al, 2011). Here, we present Hdac3 as being critical for
regulating the fibrotic phenotype of macrophages. Deletion of Hdac3
in macrophages shifted their phenotype to an atherosclerosis benefi-
cial phenotype leading to enhanced collagen deposition and a stable
plaque phenotype. In human, atherosclerosis Hdac3 was associated
with plaque vulnerability and negatively correlated with pro-fibrotic
TGFB1 expression.
Results and Discussion
Myeloid deletion of Hdac3 enhances collagen deposition in
atherosclerotic lesions
We set out to study the role of macrophage Hdac3 in atheroscle-
rotic plaque development by use of a genetic approach. We trans-
planted atherosclerosis susceptible LDLR/ mice with bone
marrow from either Hdac3fl/fl (Hdac3wt) or Hdac3fl/fl-LysMCre
(Hdac3del) mice and subsequently fed them a high cholesterol diet
(HCD) for 10 weeks. Upon sacrifice, Hdac3del-transplanted mice
displayed significantly larger lesions compared to controls (Fig 1A
and B). Plaque phenotype analysis showed a major increase in
the proportion of collagen rich fibrous cap atheromas and a
concomitant decrease in thin fibrous cap atheromas in Hdac3del-
transplanted mice (Fig 1C). By quantifying the collagen content,
we indeed observed increased collagen deposition in atheroscle-
rotic plaques of Hdac3del mice (Fig 1D and E). Polarization
microscopy revealed that lesions of Hdac3del-transplanted mice
had an increase of the most mature and stable red collagen
(Junqueira et al, 1979) subtype (Supplementary Fig S1A and B).
Moreover, a two-fold thicker fibrous cap was observed in the
Hdac3del-transplanted mice (Fig 1F and G). There was no differ-
ence in the amount of a-smooth muscle actin (a-SMA)-positive
cells (myofibroblasts and vascular smooth muscle cells, VSMCs)
in the lesions (Fig 1H), indicating that enhanced collagen deposition
is not due to increased VSMC numbers. Overall, Hdac3del mice had a
favorable plaque phenotype since it showed major features of
improved stability and increased plaque size were solely attributable
to enhanced collagen deposition.
VSMCs produce more collagen as a result of enhanced TGF-b
secretion by Hdac3del macrophages
To establish the molecular mechanism underlying increased colla-
gen deposition in lesions of Hdac3del-transplanted mice, we
measured collagen deposition in primary mouse VSMCs treated with
supernatants from oxLDL-stimulated Hdac3wt or Hdac3del bone
marrow-derived macrophages (BMMs). Interestingly, we observed
increased collagen production by VSMCs in response to superna-
tants from oxLDL-stimulated Hdac3del BMMs (Fig 1I) without effects
on VSMC proliferation (Supplementary Fig S2A). These data indi-
cate that Hdac3 deletion induces a soluble macrophage-secreted
factor that drives collagen production by VSMCs. To identify candi-
dates mediating such effects, we analyzed microarray data from
Hdac3wt and Hdac3del macrophages (Mullican et al, 2011). Ingenu-
ity pathway analysis (IPA) revealed that Transforming Growth
Factor b (TGF-b) signaling is prominently upregulated in Hdac3del
macrophages (Fig 1J). TGF-b is a pleiotropic cytokine that can be
secreted by many different cell types, including macrophages and
regulatory T cells. It deactivates effector macrophages, inhibits
CD4+ T-cell proliferation, and induces a fibrotic program in fibro-
blasts and smooth muscle cells (Li et al, 2006). As a consequence,
TGF-b is generally considered to be an anti-atherosclerotic cytokine
dampening immune responses and stabilizing atherosclerotic
lesions (Mallat et al, 2001; Lutgens et al, 2002; Reifenberg et al,
2012). Further analyzing macrophages, we indeed found enhanced
Tgfb1 gene expression in oxLDL-treated Hdac3del BMMs (Fig 1K)
and increased TGF-b secretion by these cells (Fig 1L). Enhanced
VSMC collagen production in response to supernatants from
Hdac3del BMMs was solely dependent on TGF-b secretion by these
cells, as antibody mediated blockade of TGF-b completely abolished
the difference in collagen production induced by Hdac3 deletion
(Fig 1M). Subsequent analysis of ChIP-seq data (Mullican et al,
2011) revealed that Hdac3 directly binds near the Tgfb1 promoter
(Supplementary Fig S2B), and in line with its deacetylase activity,
we observed increased histone acetylation at the Tgfb1 locus in
Figure 1. Myeloid Hdac3 deletion results in more stable atherosclerotic lesions.
A–H LDLR/ mice were transplanted with bone marrow from Hdac3wt and Hdac3del donors and sacrificed after 10 weeks HCD. (A, B) Aortic root lesions were stained
with Toluidin Blue, and aortic lesion area (n = 19/18) was quantified. P = 0.0085. (C) Plaque severity (n = 19/18) was scored. (D, E) Collagen content was assessed
using Sirius Red staining (n = 19/18). P = 0.0218. (F, G) Minimal cap thickness (n = 18/16) was measured at the thinnest region of the fibrotic cap. P = 0.003.
(H) Vascular smooth muscle cells (VSMC)/myofibroblast area (n = 14/13) was quantified using an a-SMA antibody.
I Primary mouse VSMCs were incubated with bone marrow-derived macrophage (BMM) supernatants of 50 lg/ml oxLDL-stimulated Hdac3wt and Hdac3del BMMs
for 24 h. VSMC collagen production was measured and expressed relative to the response to supernatants of Hdac3wt BMMs. One out of four representative
experiments is shown. P = 0.0001, compared to Hdac3wt macrophages.
J Upstream regulator analysis was performed on wild-type and Hdac3del BMMs.
K Tgfb1 gene expression (P = 0.0106) in oxLDL-stimulated BMMs was measured and normalized to household genes.
L TGF-b secretion (P = 0.0057) was measured in the BMM supernatants by ELISA.
M VSMC collagen was measured after 24 h incubation with BMM supernatants with 20 lg/ml control IgG (P = 0.0005) or anti-TGF-b antibody.
N ChIP for AcH3K9/14 was performed on oxLDL-stimulated BMMs, followed by PCR for the Tgfb1 gene (P = 0.0047) and for the Igk gene as a negative control.
Data information: unpaired t-test (A–H, K, L), 1-way (I), and 2-way ANOVA (M, N) with Bonferroni correction were performed for statistical analysis. All in vitro
experiments were performed at least twice in triplicate. Error bars indicate SEM.
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Figure 2. Myeloid Hdac3 deletion shifts plaque macrophages phenotype and reduces lipid accumulation.
A Macrophage area was determined using Moma-2 staining (n = 18/17).
B Dectin1 (n = 19/15, P = 0.0011) was expressed as percentage of total lesion area.
C NOS2+ (n = 18/18, P = 0.0489) cells were counted and corrected for lesion size.
D Lipid content (n = 19/18, P = 0.0149) was quantified using Oil Red O.
E Macrophage size within plaques was determined by dividing the size of an allocated macrophage area by the number of macrophages (n = 10/8, P = 0.0238).
F PMs from Hdac3wt and Hdac3del-transplanted LDLR/ mice (n = 4/5, P = 0.0096) were harvested and stained with Oil Red O, and positive cells were counted as
percentage of total macrophages.
G Gene expression (n = 4) of PPARc target genes, P = 0.0001 for all three.
H Gene expression (n = 4) of LXR target genes Abca1 (P = 0.0001), Fasn (P = 0.0018), and Scd2 (P = 0.0001).
I, J Distribution of Hdac3 and NCoR ChIP-seq tag densities at PPARc and LXR peaks.
K Efflux of AcLDL loaded BMMs to ApoA1 (P = 0.0074) or HDL (P = 0.0001), n = 3.
Data information: unpaired t-test (A–F) or, in case of multiple testing, 2-way ANOVA with Bonferroni correction (G, H, K) was performed for statistics. Error bars indicate
SEM.
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oxLDL-stimulated Hdac3del macrophages (Fig 1N). Similarly,
Hdac3del peritoneal macrophages (PMs) from transplanted LDLR/
mice also showed upregulation of Tgfb1 expression and increased
histone acetylation in the same region (Supplementary Fig S2C–E).
Thus, Hdac3 targets the Tgfb1 locus, and its deletion leads to hyper-
acetylation, subsequent increased Tgfb1 expression and secretion,
stimulating VSMCs to produce collagen.
Hdac3 deletion shifts plaque macrophages to an
anti-inflammatory phenotype and reduces lipid accumulation
To further characterize the inflammatory profile of the lesions,
immunohistochemical analysis of the plaques was performed.
Although total macrophage area was unaltered between groups
(Fig 2A), myeloid Hdac3 deletion did result in increased levels of
Dectin1+ macrophages in the lesions (Fig 2B). Interestingly, Dectin1
is a marker for alternatively activated macrophages, and particularly
upregulated in wound healing, tissue repair, and fibrosis in which
TGF-b is an important mediator (Daley et al, 2010; Brancato &
Albina, 2011). Concomitantly, there were less NOS2+ cells (Fig 2C),
further implying a decreased pro-inflammatory profile of Hdac3del
lesions. There was no difference in necrotic core size or immune cell
infiltration in the lesions (Supplementary Fig S3). Weight, plasma
triglycerides, cholesterol levels, cholesterol profile, and main
immune cell populations in the blood were also unaltered (Supple-
mentary Fig S4).
Plaque lipid content (Fig 2D) and macrophage size (Fig 2E) were
decreased in lesions of Hdac3del-transplanted mice, indicating
reduced foam cell formation. Indeed, peritoneal macrophages from
Hdac3del-transplanted mice revealed decreased lipid accumulation
(Fig 2F). Pathway analysis (Fig 1J) indicated that both PPARc and
LXR pathways may be upregulated in Hdac3del macrophages. Hdac3
functions in the NCoR repressor complex repressing PPARc and
LXR responses in the absence of ligands (Glass & Ogawa, 2006).
Recent data show that deletion of NCoR, disrupting the complex,
leads to hyperactivity of LXR and PPARc in macrophages (Li et al,
2013) or adipocytes (Li et al, 2011), respectively. Likewise, in the
absence of Hdac3, we found several PPARc and LXR target genes to
be upregulated in macrophages (Fig 2G and H). Analysis of ChIP-
seq data showed a large overlap between NCoR and Hdac3 peaks
and an overlap of approximately 50% of PPARc and LXR peaks with
Hdac3 peaks (i.e., at the Cd36 locus, Supplementary Fig S5). Consis-
tently, Hdac3 and NCoR tag densities were enriched at both PPARc
and LXR peaks (Fig 2I and J). In line with augmented PPARc and
LXR signaling, Hdac3del macrophages showed enhanced lipid
efflux capacity (Fig 2K). Overall, myeloid Hdac3 deletion results in
less vulnerable lesions that are characterized by reduced lipid
accumulation and a shift in macrophage phenotype toward an
anti-inflammatory pro-fibrotic gene program.
HDAC3 is overexpressed in human ruptured atherosclerotic
lesions and negatively correlates with plaque-stabilizing TGFB1
Our experimental data in mice show that macrophage Hdac3 dele-
tion shifts atherosclerosis to a more stable, less inflammatory
profile indicating a beneficial macrophage phenotype. To evaluate
the relevance of these findings for human atherosclerosis, we next
studied human atherosclerotic plaque specimen. We first assessed
gene expression of HDAC1-10 in a cohort of 40 stable versus
ruptured human atherosclerotic plaques (Goossens et al, 2010).
Interestingly, HDAC3 was the sole Hdac upregulated in ruptured
plaques (Fig 3A). Moreover, further analysis of HDAC3 gene
expression in atherosclerotic lesions showed that HDAC3 strongly
correlated with macrophage marker CD68 (Fig 3B). Immunohisto-
chemical analysis showed that Hdac3 particularly localized to
CD68+ rupture-prone shoulder and cap regions of human plaques
but not to adventitial areas (Fig 3C and D) indicating a distribution
pattern of Hdac3 similar to pro-inflammatory macrophages (Stöger
et al, 2012). This was further substantiated with the finding that
HDAC3 expression correlated positively with CD86 (Fig 3E) and
HLA-DPB1 (Supplementary Fig S6) mRNA expression, both mark-
ers for activated macrophages. Finally, we found an inverse corre-
lation of HDAC3 with TGFB1 gene expression (Fig 3F),
corroborating our finding that in mice Hdac3 deletion induces
TGF-b expression and a stable plaque phenotype. These data show
that Hdac3 is upregulated in ruptured human atherosclerotic
plaques, associates with activated macrophages, and inversely
correlates with pro-fibrotic TGFB1 expression.
In conclusion, to our knowledge we are the first to show that
targeting the macrophage epigenome can be applied to switch
macrophages to an atherosclerosis-favorable phenotype. Our studies
show that macrophage Hdac3 deletion is beneficial in atherosclerotic
mice. Previous work showed that endothelial silencing of Hdac3
reduces cell survival and enhances atherosclerosis development
(Zampetaki et al, 2010). These data and our current study thus
underscore the cell-specific functions of Hdac3 in atherosclerosis. We
found that macrophage-specific targeting increased fibrosis in athero-
sclerotic plaques and identified TGF-b as the critical mediator of the
pro-fibrotic phenotype of Hdac3del macrophages. Moreover, we could
demonstrate decreased lipid accumulation, which is also favorable in
atherosclerosis. Also in human lesions, Hdac3 was directly linked to
plaque stability, as Hdac3 was the sole Hdac upregulated in ruptured
lesions and inversely correlated with plaque-stabilizing TGF-b. Our
findings show that fine-tuning the macrophage phenotype by altering
the epigenetic landscape can be used to influence disease outcome.
Materials and Methods
Mice experiments
All mice were on a C57Bl/6 background. LDLR/ mice were
obtained from Charles River. Bone marrow transplantation (BMT)
was performed as described elsewhere (Goossens et al, 2010).
Briefly, 40 (20 per group, number based on previous BMT experi-
ments) 10 week old LDLR/ mice were randomly divided over
filter-top cages and provided antibiotics water (autoclaved tap water
with neomycin (100 mg/l, Sigma) and polymyxin B sulfate
(60,000 U/l, Invitrogen)) from 1 week pre-BMT till 5 weeks post-
BMT. The animals received 2 × 6 Gy total body irradiation on two
consecutive days. Bone marrow was isolated from 6 LysMCre-
Hdac3fl/fl mice (Hdac3del) and 6 Hdac3fl/fl littermates (Hdac3wt),
resuspended in RPMI1640 (Gibco) 5 U/ml heparin 2% iFCS (Gibco),
and 107 bone marrow cells were injected intravenously per irradi-
ated mouse. Bone marrow transplantation efficiency was determined
with qPCR for LDLR on DNA isolated from blood (GE Healthcare),
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and BMT efficiency was 95.6  0.9% and did not differ between
groups. Six weeks after the BMT, the mice were put on a HCD
(0.15% cholesterol, 16% fat, Arie Blok Diets) for 10 weeks. After
sacrifice, hearts were taken out and frozen in tissue-tek (DAKO)
for histology. Blood samples were taken before the start of the diet
and before sacrifice for lipid profiling and immune cell FACS and
counts. One mouse was sacrificed before the end of experiment as
a result of too much weight loss (> 15%), and no other mice were
excluded. All animal experiments were conducted at the University
of Amsterdam and approved (permit: DBC10AC) by the Committee
for Animal Welfare of the Academic Medical Center, University of
Amsterdam.
Histology
Atherosclerotic lesions from the heart were cut in sections of
7 lm on a Leica 3050 cryostat at 25°C and stained with Toluidin
Blue (0.2% in PBS, Sigma) to determine lesion size and Sirius
Red (0.05% in saturated picric acid solution, Sigma) for measur-
ing fibrosis. Polarization microscopy on Sirius Red stained slides
was performed for identifying collagen subtypes. Positive areas
were quantified using Adobe Photoshop 5.5 (Adobe) blindly, with-
out knowledge of genotype. The lesions were also typed blindly
according to severity as early (intimal xanthoma), moderate (path-


















Figure 3. Hdac3 is expressed in human atherosclerotic plaque macrophages, especially in inflammatory regions.
A Microarray which was performed on RNA from ruptured and paired stable control segments (n = 20, respectively). HDAC3 (P = 0.00007), HDAC5 (P = 0.00005),
HDAC7b (P = 0.0003), HDAC9 (P = 0.00004).
B Correlation of HDAC3 with macrophage marker CD68 in gene expression data from human atherosclerotic lesions (n = 40). Statistical analysis was performed with
Pearson’s correlation test.
C, D Hdac3 is present in CD68+ areas in plaque shoulder (n = 21) and cap (n = 14) regions, while CD68+ areas in the adventitia (n = 12) showed negligible
co-localization with Hdac3. Error bars indicate SEM. P = 0.0001 compared to both shoulder and cap regions with 1-way ANOVA.
E Correlation of HDAC3 with the pro-inflammatory marker CD86.
F Correlation of HDAC3 with the pro-fibrotic gene TGFB1.
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fibrous atheroma), as described before (Kanters et al, 2003;
Lutgens et al, 2010). Lesions were fixed in acetone and incubated
with antibodies against macrophages (MOMA-2, 1:4,000, AbD
serotec), granulocytes (NIMP, directed against Ly6G (Lopez et al,
1984), 1:400, kind gift of P. Heeringa, UMC Groningen), T cells
(KT3, directed against CD3, 1:250, AbD serotec), infiltrating
macrophages (ER-MP58, 1:100, AbD serotec), and Dectin1
(a-Dectin1, clone BD6, 1:250, AbD serotec). A rabbit anti-rat
biotin labeled antibody (1:300, DAKO) was used as secondary
antibody. Staining was amplified with an ABC kit and visualized
using an AEC kit (both Vector Labs), and cell nuclei were stained
with hematoxylin (Merck). For a-SMA (FITC, 1:2,000, Sigma)
positive cells, anti-fluorescein-POD (1:500, Roche) was used and
visualized using an AEC kit. For NOS2 (1:200, ab15323, Abcam)
staining, Brightvision poly-HRP was used as secondary antibody
and visualized using an AEC kit and counted blindly. Human
lesion stainings were performed as described elsewhere (Stöger
et al, 2012). All proceedings were in agreement with the Dutch
Code of Conduct for Observational Research with Personal Data
(2004) and Tissue (2001). For Hdac3, slides were incubated with
a-Hdac3 (1:100, Santa Cruz), and Brightvision poly-HRP was used
as secondary antibody and visualized using an AEC kit.
Lipid profile
Cholesterol and triglyceride levels in the blood were measured with
a standard protocol from commercially available kits (Roche). Lipo-
protein profiles were determined by fast-performance liquid chro-
matography (FPLC), as described previously (Seijkens et al, 2014).
Individual mouse samples were combined in three pools per geno-
type, and the data presented are the mean of those three pools.
Immune cell counts
Blood was collected at sacrifice. Erythrocytes were removed by incu-
bation with erylysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA in PBS, pH 7.4). Non-specific antibody binding was prevented
by pre-incubation with an Fcc-receptor blocking antibody (clone 93,
eBioscience). Leukocytes were labeled with CD3-FITC (eBioscience),
B220-V500 (eBioscience), CD11b-PeCy7 (BD), Ly6G-PE (BD), and
Ly6C-APC (Miltenyi Biotec). Cells were analyzed on a FACSCanto II
flowcytometer (BD). The following populations were detected: T
cells (CD3+), B cells (B220+), granulocytes (Ly6G+, CD11b+),
monocytes (Ly6G, CD11b+), and Ly6Chi and Ly6Clow monocytes.
Peritoneal macrophages
Bone marrow transplantation was performed, as described. Mice
were put on a HCD for 10 weeks and subsequently injected with
thioglycollate medium (3%, Fischer). Four days after injection, mice
were sacrificed and the peritoneum was flushed twice with 10 ml
PBS to collect peritoneal macrophages. Flushed thioglycollate-
elicited macrophages were cultured in RPMI-1640 25 mM HEPES,
2 mM L-glutamine, 10% FCS, penicillin (100 U/ml), and streptomy-
cin (100 lg/ml) (all Gibco) and allowed to adhere for 3 h. Oil Red O
staining (0.3% in 60% isopropanol, Sigma) was performed to deter-
mine lipid accumulation. For gene expression experiments, macro-
phages adhered overnight.
Chromatin immunoprecipitation
ChIP was performed as described elsewhere (Spann et al, 2012).
ChIP-qPCR was performed on an ABI ViiA7 using SYBR Green Fast
(ABI). Relative enrichments are presented as percentage input.
Primer sequences are available on request.
ChIP sequencing and microarray pathway analysis
Data analysis was performed using HOMER (Heinz et al, 2010) on
previously published ChIP experiments: GSE33596 (Mullican et al,
2011), GSE27060 (Barish et al, 2012), GSE21314 (Lefterova et al,
2010), and GSE50944 (Li et al, 2013). Each sequencing experiment
was normalized to a total of 107 uniquely mapped tags and
visualized by preparing custom tracks for the UCSC genome
browser. Microarray data were available through GSE33596, and
pathway analysis was performed using IPA. Upstream regulator
analysis was performed, and upstream regulators were ranked on
z-score, which is a statistical test used to define the overlap between
differentially expressed genes and genes that are known to be
affected by the upstream regulator.
BMM culture
Femurs and tibia were flushed with ice-cold PBS. Bone marrow cells
were cultured in RPMI-1640 25 mM HEPES, 2 mM L-glutamine,
10% FCS, penicillin (100 U/ml), and streptomycin (100 lg/ml) (all
Gibco) supplemented with 15% L929-conditioned medium for
8 days. BMMs were stimulated with 50 lg/ml oxLDL (BTI) for 24 h.
qPCR analysis was performed for gene expression, and supernatants
were used for VSMC collagen production assays.
Cholesterol efflux
Macrophages were loaded overnight with 25 lg/ml 3H-labeled
acLDL in RPMI-1640 with 1% BSA. Cells were washed four times
with PBS-2% BSA. Then, they were incubated with RPMI-1640 with
and without ApoA1 and HDL as acceptors. After 4 h, macrophages
were lysed in 2-propanol and radioactivity was measured in both
media and cell lysates.
RNA analysis
RNA was isolated with High Pure RNA Isolation kits (Roche) from
500,000 cells according to manufacturer’s protocol. cDNA was
synthesized from 500 ng total RNA with iScript (Bio-rad). qPCR was
performed with 4 ng cDNA using Sybr Green Fast (Applied Biosys-
tems) on a ViiA7 PCR machine (Applied Biosystems). Gene expres-
sion was normalized to the mean of ARBP and GAPDH expression.
Primer sequences are available on request.
VSMC culture
Primary mouse VSMCs were isolated and cultured in DMEM/F12
20% FCS (Gibco) for a maximum of 10 passages on 0.1% gelatin
coated plates (Rensing et al, 2014). Fifty thousand VSMCs were
plated per well; after overnight adherence, cells were starved (0%
FCS) for 48 h and then incubated with macrophage supernatants for
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24 h with and without 20 lg/ml control IgG or anti-TGF-b antibody
(Dasch et al, 1989). For collagen production measurement, cells were
fixed in 3.7% formaldehyde, stained with 1% Sirius Red in 0.01 M
HCl, and lysed with 0.01 M NaOH, as previously described (Rensing
et al, 2014). Absorption was measured on a standard plate reader at
544 nm, and a gelatin standard was used for quantification. VSMC
proliferation was measured using Celltrace CSFE Cell Proliferation Kit
(10 lM, Invitrogen) according to manufacturer’s instructions.
Human transcriptomics
Gene expression data were taken from an existing database and
analyzed as described previously (Goossens et al, 2010; Stöger et al,
2012). Briefly, microarray analysis was performed on RNA from
ruptured and paired stable control segments (n = 20, respectively)
from human endarterectomy specimens that were obtained from the
Maastricht Pathology Tissue Collection. Plaque progression stage
was assessed by examination of hematoxylin–eosin stained slides
from flanking segments using the Virmani classification criteria by a
cardiovascular pathologist and an experienced researcher in cardio-
vascular pathology. Segments designated as stable featured either a
fibrous cap atheroma or pathological intimal thickening. Segments
designated as ruptured included a thrombus and/or presented
intraplaque hemorrhage. Sections were considered stable or
ruptured if they were flanked at both sides within the same endar-
terectomy specimen, by segments of identical progression stage.
Only endarterectomy specimens were used, which contained both
stable and ruptured plaque segments. All use of tissue and patient
data was in agreement with the “Code for Proper Secondary Use of
Human Tissue in the Netherlands”. Illumina Human Sentrix-8 V2.0
BeadChip technology was used to determine mRNA expression.
Statistical analysis
Data are presented as mean  SEM. The statistical analyses were
performed using GraphPad Prism 5.0 software using unpaired t-test
and 1-way or 2-way ANOVA with Bonferroni correction for grouped
analyses. P-values < 0.05 were considered statistically significant.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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